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Abstract: Lifestyle modification based on behavior therapy is the most important and effective 
strategy to manage the metabolic syndrome. Modern lifestyle modification therapy combines 
specific recommendations on diet and exercise with behavioral and cognitive strategies. The 
intervention may be delivered face-to-face or in groups, or in groups combined with individual 
sessions. The main challenge of treatment is helping patients maintain healthy behavior changes 
in the long term. In the last few years, several strategies have been evaluated to improve the 
long-term effect of lifestyle modification. Promising results have been achieved by combining 
lifestyle modification with pharmacotherapy, using meals replacement, setting higher physical 
activity goals, and long-term care. The key role of cognitive processes in the success/failure of 
weight loss and maintenance suggests that new cognitive procedures and strategies should be 
included in the traditional lifestyle modification interventions, in order to help patients build a 
mind-set favoring long-term lifestyle changes. These new strategies raise optimistic expectations 
for an effective treatment of metabolic syndrome with lifestyle modifications, provided public 
health programs to change the environment where patients live support them.
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Introduction
The metabolic syndrome (MS) is a clinical condition characterized by a cluster of 
abnormalities, including visceral obesity, hyperinsulinemia and insulin resistance,1 
type 2 diabetes, dyslipidemia, hypertension, fatty liver, and elevated uric acid, a 
procoagulant state, whose borders are only provisionally set by different international 
agencies (Table 1).2–5 The focus is given to visceral obesity,6 which is considered the 
pivotal alteration according to the International Diabetes Federation,4 and to atherogenic 
dyslipidemia, which covers two of the five diagnostic criteria. The prevalence of MS 
is increasing worldwide in parallel with the alarming rise of obesity;7 according to 
the National Health and Nutrition Examination Survey, MS is estimated to affect up 
to 36% of the US adult population,8 with a lower prevalence in Europe.9 Although the 
accepted cutoffs of individual variables do not constitute per se evidence of risk factors, 
the clustering of abnormalities carries a high risk of the diabetes and cardiovascular 
diseases. In particular, the presence of MS is associated with a two- to four-fold increase 
of cardiovascular disease-related morbidity and mortality,10,11 even in the absence of 
clinically evident cardiovascular disease or diabetes mellitus.12,13
MS affects people whose excess weight and sedentary life determine the 
phenotypical expression of a genetically acquired trait. The balance between genes 
and environment in disease expression is variable, but maintaining normal weight Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Table 1 Diagnostic criteria of the MS, according to the most popular proposals (National Cholesterol education Program, international 
Diabetes Federation, and the Joint interim Statement of several international Associations and Agencies)
Criteria for diagnosis NCEP (ATP-III)2 IDF4 Joint Interim Statement5
Any three of the  
following
Visceral obesity + two  
of the remaining
Any three of the  
following
visceral obesity waist circumference .102 cm (M)  
or .88 cm (F)
waist circumference $94 cm  
(M) or $88 cm (F)a
waist circumference $94 cm  
(M) or $88 cm (F)a
Atherogenic dyslipidemia HDL-Chol ,40 mg/dL (M) 
or ,50 mg/dL (F)
HDL-Chol ,40 mg/dL (M)  
or ,50 mg/dL (F)
HDL-Chol ,40 mg/dL (M)  
or ,50 mg/dL (F)
Triglycerides $150 mg/dL  
or drug-treated
Triglycerides $150 mg/dL  
or drug-treated
Triglycerides $150 mg/dL  
or drug-treated
Altered glucose regulation Blood glucose $110 mg/dL  
or treated for diabetesb
Blood glucose $100 mg/dL  
or treated for diabetes
Blood glucose $100 mg/dL  
or treated for diabetes
elevated arterial pressure Arterial pressure $130/85 mmHg  
or treated for hypertension
Arterial pressure $130/85 mmHg  
or treated for hypertension
Arterial pressure $130/85  
mmHg or treated for hypertension
Notes: aThese cutoffs are valid for Caucasians. Different cutoffs are reported for individuals of different ethnic origin; bLater reduced to 110 mg/dL.
Abbreviations: NCeP, National Cholesterol education Program; iDF, international Diabetes Federation; ATP-iii, Adult Treatment Panel iii.
and practicing physical activity remain the primary and 
most effective prevention strategy.14 Similarly, treatment 
should be based on the promotion of effective weight loss 
and physical exercise, but attempts at engaging patients 
in healthy lifestyles and at maintaining the results require 
specific strategies.14 Patients’ adherence to nutritional pre-
scription and motivation to practice daily physical activity 
progressively reduce in the course of time and with treatment 
length,15 and metabolic improvements rapidly vanish with 
weight regain. Long-term lifestyle modification strategies 
are necessary, and behavioral procedures represent the most 
effective nonsurgical approach.16
In this article, we address the following topics: i) the 
role of lifestyle modification in the management of MS, 
ii) the principles and the main strategies of lifestyle modifi-
cations based on behavior therapy, and iii) the new frontiers 
of lifestyle modification programs.
The role of lifestyle modification  
in the management of MS
Weight reduction represents the principal goal of most inter-
vention studies on MS. There is complete agreement that 
weight loss is associated with significant improvements in the 
clinical abnormalities of MS, including blood glucose, lipid 
profile, and blood pressure,17,18 and even a moderate weight 
loss (7% reduction) in 4 weeks can improve the metabolic 
profile, despite the persistence of a high body mass index 
(BMI).19 However, the greater the BMI loss, the larger are 
the metabolic improvements.
In a 2-year study, 41 obese patients were assigned to a 
long-term diet and lifestyle modification therapy.20 Two-thirds 
of patients who achieved a weight loss of 10% or more did 
no longer meet the diagnostic criteria of MS, whereas in 
patients who lost ,10%, the prevalence of MS remained 
high (81%).
Lifestyle modifications are also desirable in subjects 
who have only one or two criteria of MS, not the full-blown 
disorder. In the large US Diabetes Prevention Program 
(DPP), the effects of lifestyle intervention have been inves-
tigated in more than 3000 participants with impaired glucose 
tolerance.21 The patients in the intervention group were 
allocated to an intensive lifestyle intervention (including 
a low-calorie, low-fat diet and weight loss) or to the met-
formin therapy (850 mg three times daily.). MS incidence 
was reduced by 41% in the lifestyle group (P , 0.001) and 
by 17% in the metformin group (P = 0.03) compared with 
the placebo arm. Among participants who already met the 
criteria for MS at baseline, 38% in the lifestyle group, 23% 
in the metformin group, and 18% in the placebo group no 
longer had the syndrome after a mean follow-up of 3.2 years. 
This demonstrates that lifestyle changes can, by themselves, 
reverse the metabolic abnormalities of MS. Similarly, the 
effects of lifestyle modification have been measured in the 
Finnish Diabetes Prevention Study.22 A cohort of 522 middle-
aged, overweight subjects with impaired glucose tolerance 
was randomized either to a usual care control group or to 
an intensive lifestyle intervention group. The control group 
received general dietary and exercise advice at baseline 
and had a yearly medical examination. The subjects in the 
intervention group received additional individualized dietary 
counseling from a nutritionist. They were also offered circuit-
type resistance training sessions and advised to increase 
overall physical activity. After 3 years, the intervention 
produced significantly larger effects on weight loss, dietary Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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fat intake, moderate-to-severe leisure time physical activity, 
fasting glucose and lipid concentrations,22 and the incidence 
of diabetes was significantly reduced in comparison to 
controls (11% versus 23%, P , 0.001).23 The intervention 
program was more intensive during the first year, when the 
changes in clinical characteristics were particularly large. In 
a secondary analysis,24 after a mean follow-up of 3.9 years, 
the intervention group reached a significant reduction in 
the prevalence of MS and visceral obesity compared to the 
control group. When compared to the results of the DPP 
study, in the Diabetes Prevention Study, the prevalence of 
MS in the control group tended to be lower, indicating that 
the ‘mini-intervention’ carried out in the control arm had 
some effect on the occurrence of MS.
In addition, the macronutrient composition of diet, not 
only the caloric deficit, may be important in the management 
of MS. In the SUN prospective cohort,25 a Mediterranean-style 
diet (high consumption of fruit, vegetables, legumes, grain, 
moderate alcohol intake, a moderate-to-low consumption of 
dairy products and meats/meat products, and a high monoun-
saturated-to-saturated fat ratio) was inversely associated with 
the cumulative incidence of MS. In the PREMIER study,26 
the Dietary Approaches to Stop Hypertension diet (rich in 
fruit, vegetables, and low-fat dairy foods, and low in saturated 
and total fat intake) plus lifestyle interventions improved the 
metabolic parameters, particularly blood pressure.
In the treatment of MS, physical activity has a pivotal 
role. Cardiorespiratory fitness was reported to modulate 
the relationship between MS and fatal events, providing a 
strong protective effect against all-cause and cardiovascular 
mortality.27,28 The amount and the intensity of physical 
exercise regulated the circulating levels of lipids and other 
metabolic abnormalities responsible for cardiovascular risk.29 
When combined with diet, physical activity exerted a greater 
effect compared with studies where either approach is prac-
ticed alone.30 In particular, adding aerobic exercise training to 
nutritional weight-reducing approach resulted in many more 
cases resolving (95% versus 75%) or improving (adjusted 
odds ratio, 3.68) MS compared to diet alone.31
The intensity of physical activity required to improve 
metabolic parameters is not defined. Even a low-intensity exer-
cise training for a 2-month period improved some metabolic 
abnormalities,32 but an exercise dose–response was reported 
on the components of MS.33 Several studies confirmed that 
higher levels of physical activity are associated with lower 
prevalence and incidence of MS and cardiovascular risk fac-
tors in cross-sectional and prospective studies.34–36 In a recent 
analysis of the National Health and Nutrition Examination 
Survey data,37 maintaining an active lifestyle, as assessed by the 
number of daily steps measured by an accelerometer, reduced 
the prevalence of MS and cardiovascular risk factors.
In summary, lifestyle modification programs are neces-
sary to maintain metabolic changes in the long period, and 
such programs should always address both nutritional treat-
ment and physical activity.38,39
Principles and main strategies of 
lifestyle modifications based  
on behavior therapy
Behavior therapy has been designed to provide patients with 
a set of principles and techniques to modify their eating and 
activity habits.40 Originally, the treatment was exclusively 
based on the learning theory (ie, behaviorism). The theory 
postulates that the behaviors causing obesity (excess eating 
and low exercising) are largely learnt and therefore could 
be modified or relearnt.41–43 The theory also postulated that 
positive changes in eating and exercising can be achieved 
by modifying the environmental cues (antecedents) and the 
reinforcements of these behaviors (consequences).43 The 
intervention was later integrated with cognitive strategies 
(eg, problem solving and cognitive restructuring) and with 
specific recommendations on diet and exercise.44 The treat-
ment is different from typical psychotherapy. The aim is not 
to treat a psychiatric disorder, but rather to change eating and 
exercise behaviors. In addition, lifestyle intervention does 
not address the potential causes of the problematic behaviors, 
but it is focused to teach skills to change them.40
How to deliver lifestyle modification 
treatment
In research settings, lifestyle modification treatments have 
been delivered in individual sessions (as was in the DPP)45 
or in groups of ∼10–20 participants46 or in groups combined 
with individual sessions (as in the Look AHEAD study).47 
Outside research settings, lifestyle modification treatment 
should be delivered by a multidisciplinary team composed 
of physicians and nonphysician health professionals, such as 
dieticians or professionals with a master degree in exercise 
physiology, behavioral psychology, or health education.48 
Within these multidisciplinary teams, physicians should 
limit their intervention to the initial assessment, the manage-
ment of medical complication, the engagement in lifestyle 
modification treatment, and in a periodic medical evaluation; 
nonphysician health professionals should be actively involved 
in the delivery of lifestyle modification treatment.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
376
Dalle Grave et al
Although both individual and group treatment strategies 
are effective, a study found that participants who were ran-
domized to receive group-based therapy lost significantly 
more weight than those who were treated individually.49 
Despite the benefits of group treatment, several clinicians 
believe that individual contact is critical to keep patients 
in long-term treatment.47 The development of a trusting 
relationship between clinicians and patients is consid-
ered as a safety net for participants who stop attending 
group sessions regularly, a common event after the first 
6–12 months.50,51
Frequency and duration of lifestyle 
modification treatment
Lifestyle modification programs generally offer patients 
with obesity an intensive first phase, consisting of 16–26 
weekly sessions.46,52 After 6 months, weight loss tends to 
reach a plateau, irrespective of treatment strategies, exclud-
ing bariatric surgery,52,53 and weekly treatment of up to 
1 year produces only marginally greater weight loss than 
that achieved in 6 months.54 Unfortunately, no definite data 
are available about the optimal duration and intensity of the 
weight maintenance phase. A few studies showed that group 
sessions delivered twice a month for 1 year after the weight 
loss phase facilitated the weight loss maintenance, while 
retaining patients in active treatment.52,55 However, continu-
ous care up to 3 years produced long-term weight loss only in 
a subgroup of obese patients and was associated with a high 
rate of attrition.56 With too intensive models, most patients 
tend to experience therapy ‘burnout’,54 particularly when 
they reach the weight loss plateau, and monotonous sessions 
favor the discontinuation of treatment.46 Noteworthy, not all 
dropouts should be considered treatment failures. Patients 
satisfied with the results obtained with treatment and those 
who were confident to lose additional weight without pro-
fessional help were shown to maintain an even larger mean 
weight loss than continuers.56
Strategies to engage patients  
in lifestyle modification
Some of the key principles and strategies to engage patients 
in lifestyle modification, derived from motivational 
interviewing,57,58 are listed below:
•	 Conceptualization of motivation. Motivation is a dynamic 
entity waxing and waning as a function of shifting per-
sonal, cognitive, behavioral, and environmental deter-
minants.59 This means that patients’ motivation may 
require continuous attention, not only during the engaging 
process, but also in the course of treatment.60
•	 Collaborative therapeutic style. Clinicians should adopt 
a collaborative therapeutic style as opposed to a confron-
tational approach.61 The collaborative style of cognitive 
behavior therapy has been considered as one of the main 
reasons for its higher success compared to other interven-
tions to engage patients with resistance.62
•	 Acceptance and change. Clinicians should validate 
patients’ experience within the framework of a bal-
ance between acceptance and change, firmness, and 
empathy.63
•	 Functional analysis. Clinicians should make a functional 
analysis of the pros and cons of changing lifestyle because 
change is facilitated by communicating in a way that 
elicits the person’s own reasons for and the advantages 
of change.57
•	 Roll with resistance. Clinicians should not address 
resistance with confrontation, but with a collaborative 
evaluation of the variables involved in maintaining the 
unhealthy lifestyle.57
•	 Support self-efficacy. Self-efficacy refers to a person’s 
belief that he/she is capable of keeping a specific 
behavior;64 it plays an important role in achieving health 
behavior change.65 In the evaluation interview, clini-
cians should promote self-efficacy by raising the hope 
that lifestyle changes can be attained. Later, during the 
program, self-efficacy should be promoted by designing 
an individualized eating and physical activity program 
that patients are confident to stick to.66
•	 Be sensitive to stigma against individuals with obesity. 
Stigma influences the decision of patients with obesity 
to start treatment.67 To prevent stigma, clinicians should 
recognize that obesity and MS are medical conditions and 
not the product of lack of willpower and treat patients 
with respect and support.67
•	 Educate patients. Clinicians should inform patients of the 
negative aspects of unhealthy lifestyles and the benefits of 
engaging in healthy behavior on the management of MS. 
Table 2 shows the main topics to cover when educating 
patients on MS and lifestyle modification. A strategy to 
promote patients’ engagement in treatment is also giving 
detailed information about aims, duration, organization 
procedures, and the results of lifestyle modification, using 
written material.16 In reluctant patients, it might be helpful 
to propose treatment as a sort of experiment, with a possible 
return to the old habits in the absence of benefits.68Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Table 3 Practical recommendations for diet and physical exercise 
in lifestyle modification programs
Dietary recommendations16
1000–1200 kcal/day for overweight women, and 1200–1600 kcal/day for 
overweight men and heavier for more active women
The diet should provide $55% calories from carbohydrates, #30% from 
lipids (7%–10% from saturated fats), and ∼15% from proteins
Total calories should be moderately increased according to the daily 
amount of physical activity
Diets are designed to create a calorie deficit of 500–1000 kcal/day, 
producing a weight loss of 0.5–1.0 kg/week
Physical exercise recommendations77
engage in moderate-to-vigorous exercise for at least 60 min on most 
days (at least 5 days/week)
walking may be the favorite exercise, as unstructured exercise may be 
included in routine daily activities
Check the baseline number of steps by a pedometer, then add 500 steps 
at 3-day intervals to a target value of 10,000–12,000 steps/day
Jogging (20–40 min/day), biking, or swimming (45–60 min/day) may 
replace walking
Physical exercise is intended to produce a calorie deficit of at least 
400 kcal/day, favoring weight loss, maintaining muscle mass, and 
preventing weight cycling
Notes:  The  aim  of  behavior  therapy  is  to  provide  patients  with  cognitive  and 
behavioral skills to modify their lifestyle. Accordingly, these recommendations should 
not be intended as prescriptions, but should be tailored on patients’ preferences.
Table 2 Main topics to cover when educating patients on MS and 
on lifestyle modification
1. Definition and diagnosis
The MS is a cluster of conditions that increase the risk of developing 
vascular disease (heart disease, strokes, and peripheral vascular disease)
For diagnosis, see Table 1
2. Prevalence
MS affects up to 25% of the population in the United States7 and 15% of 
the population in europe9
it increases with age (,10% in individuals aged 20–29, 20% in individuals 
aged 40–49, and 45% in individuals aged 60–69)7
The ‘obesity epidemic’ is considered the main factor responsible for the 
increasing prevalence of MS6
3. Causes
it is linked to insulin resistance.1 The causes of insulin resistance have 
not yet been completely clarified. It probably involves a variety of 
genetic and environmental factors. Both being overweight and inactive 
contribute to the disease state
4. Consequences
MS increases the risk of developing type 2 diabetes11 and CvD and the 
risk for CvD mortality10
Other conditions that are associated with MS are, notably, polycystic 
ovary syndrome, fatty liver, cholesterol, gallstones, asthma, sleep 
disturbances, and some forms of cancer6
5. Management
Weight loss with lifestyle modification (hypocaloric diet, increased 
physical activity, and cognitive behavior therapy to help patients modify 
eating and activity habits) is the key procedure to manage MS.2 Research 
data indicate that a lifestyle intervention produce a marked reduction in 
the prevalence of MS and a decline of body weight, waist circumference, 
fasting glucose, triglycerides, and blood pressure.21 The treatment may 
be delivered in groups and/or individually by a multidisciplinary team 
trained in lifestyle modification, which includes a registered dietitian, 
a behavioral psychologist, and an exercise specialist, coordinated by a 
physician. It includes weekly sessions for the first 6 months, followed by 
two sessions a month in the following 6 months
Specific treatment of lipid (eg, hypertriglyceridemia) and nonlipid risk 
factors (eg, hypertension and hyperlycemia) may be added to the lifestyle 
modification2
Abbreviation: CvD, cardiovascular disease.
Dietary recommendations
Lifestyle modification programs recommend a low-calorie 
diet, and their basic principles are reported in Table 3.16 Diets 
are intended to induce a caloric deficit of 500–1000 kcal/
day, and able to promote a weight loss of 0.5–1.0 kg/week. 
Very-low-calorie diets, with a calorie content #800 kcal/
day, are no longer recommended because, despite producing 
greater initial weight losses, they require medical monitoring 
and nutritional supplementation and have no advantages on 
long-term weight loss.50 Recently, several randomized con-
trolled trials found that low-carbohydrate diets (ie, ,30 g/
day) produced greater initial weight reductions than the more 
traditional low-calorie diets (∼1000–1200 kcal/day) described 
in Table 3.69–71 However, weight loss, metabolic outcomes, 
and dietary intake are no longer different after 36 months.72 
These data indicate that the real problem to face with dietary 
recommendation is not to identify the optimum macronutri-
ent composition but the adherence to dietary modification in 
the long term.
Adherence may be enhanced by increasing diet struc-
ture and limiting food choices, thereby reducing temptation 
and the potential mistakes on calculating energy intake.40 
A strategy to increase the diet structure is to provide patients 
with meal plans, grocery lists, menus, and recipes.73 Support 
for this strategy derives from a study showing that the provi-
sion of both low-calorie food (free of charge or subsidized) 
and structured meal plans resulted in significantly greater 
weight loss than a diet with no additional structure.73
Another effective strategy to increase dietary adherence is 
meal replacements. A meta-analysis of six controlled trials found 
that liquid meal replacement determines a 3-kg greater weight 
loss than that produced by conventional diets.74 Meal replace-
ment helps patients overcome some problems that occur when 
consuming conventional food diets (ie, underestimation of calo-
rie intake, difficulties in estimating portion sizes, macronutrient 
composition, calorie content, and in recalling the consumed 
food), and simplify food choices.46 The use of portion-controlled 
servings of conventional food is another effective strategy to 
facilitate dietary adherence and weight loss.75,76Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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exercise recommendations
An initial assessment is needed to determine the current 
level of physical activity in individual patients. It is clinically 
useful to start asking patients how they judge their present 
level of physical activity and whether they believe that it is 
adequate to lose or maintain body weight. If, as usual, patients 
report to be sedentary, the following step is asking why and 
whether there are physical or logistical barriers to exercise 
(eg, arthritis and time constraints).
Clinicians should evaluate which type of activity is 
feasible for patients, considering the barriers (see above) 
that can prevent a successful increase in physical activity. 
Accordingly, they should assist patients in developing a 
physical activity plan based on the initial assessment. Any 
type of physical activity should be encouraged.
Lifestyle modification programs recommend a moder-
ate-to-vigorous exercise for at least 60 min on most days 
(Table 3).51,77 Lifestyle activity should be increased slowly 
in intensity and duration (by 5 min/session/week), starting 
from a low-intensity exercise (∼3 metabolic equivalent) 
in sedentary subjects, to avoid excessive fatigue, muscle 
pain, strains, or injuries.45,47 Patients should be encouraged 
to register their baseline physical activity or to check their 
baseline number of steps by a pedometer. Whenever brisk 
walking is chosen as the preferred activity, they should be 
instructed to add 500 steps at 3-day intervals to a target 
value of 10,000–12,000 steps/day.16,78 Although aerobic exer-
cise may be considered as the preferred activity, resistance 
exercise and strength training should also be considered 
as effective options according to individual preferences. 
The presence of medical comorbidities (eg, hypertension, 
cardiovascular disease, MS, and diabetes) could contraindi-
cate strength training and may indicate additional medical 
workup, including exercise testing and/or appropriate medi-
cal supervision during exercise.
Exercise adherence, contrary to dietary adherence, 
increases with less structure.40 For example, patients engage 
in more physical activity when instructed to do so on their 
own at home than when asked to attend on-site, supervised, 
group-based exercise sessions.79 In addition, increasing 
lifestyle activity (eg, using stairs rather than elevators, 
walking rather than riding or using the car, and reducing 
the use of labor-saving devices) determines similar weight 
loss, but greater weight maintenance than structured, pro-
grammed activity.80–82 Finally, prescribing multiple short 
bouts (10 min each) rather than one long session may help 
patients accumulate more minutes of exercise. In summary, 
these data suggest that decreasing the structure of exercising 
probably reduces those barriers that inhibit exercise (eg, lack 
of time or financial resources).40
Behavioral procedures
Self-monitoring
The core procedure of the lifestyle modification treatment is 
based on self-monitoring of food intake, physical activity, 
and body weight;83 the larger the use of self-monitoring, the 
larger the amount of weight loss.84
Patients seeking to lose weight, in particular those who 
report difficulties in losing weight, underestimate their 
calorie intake by almost 50%.85 It is, therefore, essential to 
help patients improve their ability in estimating food intake 
by using measurement tools (such as cups, spoons, and food 
scales) and nutrition fact labels and manuals with the calorie 
content of food.40 Practical in-session exercises are useful for 
this purpose. Patients are invited to register, in a monitoring 
sheet, the time, the amount, the type, and the calorie content 
of the food and beverages they are planning to consume and 
later check during meals if they respect their plans. Any 
change should be noted in the food diary, and the amount of 
calorie intake should be recalculated. ‘Real time’ monitoring 
is a strategy that may help patients interrupt behaviors that 
are automatic and out of control.86
Physical activity can be recorded on the same monitor-
ing sheet in minutes (of programmed activity) and/or steps 
(of lifestyle activity), using a pedometer, with the intent 
to reach at least 10,000 steps/day.40 Patients interested in 
having a more precise measurement of their daily energy 
expenditure may use an accelerometer, which measures total 
expenditure, the energy expenditure in physical activity, the 
duration and the levels (in metabolic equivalent of task) of 
physical activity and sleeping time.
Patients may also benefit from recording activities, 
moods, and thoughts associated with eating and exercising. 
This information may help identify obstacles to behavior 
change. Self-monitoring records can also be used to provide 
information to identify contingencies that can be targeted 
for intervention.40
Patients are also encouraged to check their weight regu-
larly (eg, once a week), because frequent checking of weight 
is associated with better long-term weight maintenance,87 and 
to record their weight in a weight graph to assess their weight 
trend. Patients are encouraged to discuss the interpretation of 
weight change with their therapists during the group or the 
individual sessions. The weighing procedure has a number Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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of purposes. First, it provides a good opportunity to educate 
patients about their weight, about body weight in general, and 
how to interpret the number on the scales, which otherwise 
they are prone to misinterpret. It is important to educate 
patients that each reading is subjected to error, mainly due to 
variation in the hydration state. For this reason, they need to 
focus on what happened over the past 4 weeks to distinguish 
weight changes from natural fluctuations. Second, weighing 
stimulates patients to maintain a lifestyle oriented to weight 
control. Third, regular weighing may help patients address 
two problematic behaviors with a negative influence on 
lifestyle modification adherence: excessive weight checking 
and avoidance of weight checking.83 Patients with excessive 
weight checking (eg, several times a day) may reduce their 
effort to maintain a lifestyle focused on weight control if they 
misinterpret insignificant day-to-day weight oscillation as 
an increase. On the other hand, weight checking avoidance 
makes it impossible to test weight changes.
Goal setting
Patients entering lifestyle modification programs are encour-
aged to set specific and quantifiable weekly goals (ie, increasing 
physical activity by 1000 steps/week or eating only at meals), 
which should be realistic and moderately challenging.40 Goal 
achievement is associated with a sense of accomplishment, 
which is reinforcing and enhances self-efficacy,48 a construct 
associated with long-term weight loss.56
Particular attention should be paid to patients’ weight 
loss expectation, since higher weight loss expectations are 
associated with attrition.88 A few data indicate that encour-
aging participants to seek only a modest initial weight loss 
does not facilitate weight maintenance and produces a lower 
weight loss than standard treatment.89 In the initial phase of 
treatment, it is more useful to have patients focus on weekly 
weight loss (eg, losing from ½ to 1 kg per week) and to 
detect and promptly address any warning sign of weight loss 
dissatisfaction, thus minimizing the risk of attrition.88 In our 
clinical experience, unrealistic weight loss expectations may 
be easily changed later when patients have reached some 
intermediate goals and the rate of weight loss is declining. 
Specific strategies to change weight goals have been recently 
described in the modern cognitive behavioral treatments 
of obesity.83 A crucial aspect favoring the modification of 
unrealistic weight goals is the development of a trusting and 
collaborative clinician-to-patient relationship.88 This is also 
a key factor to avoid the sense of abandonment that patients 
report as one of the main reasons of attrition.90
Stimulus control
These procedures are based on the principles of classical and 
operant conditioning. Stimulus control is aimed at modifying 
the environment (ie, external eating cues) to make it more con-
ductive to choices supporting changes in eating and exercising. 
Patients should be instructed both to remove triggers of 
excessive eating (eg, keeping tempting food out of sight or 
avoiding buying it) and to increase positive cues for exercis-
ing (eg, lay out exercise clothes before going to bed) and for 
desirable behavior (eg, putting the food sheet on the table to 
facilitate its real-time compilation during eating). Stimulus 
control may also be used to reinforce the adherence to eating 
control and exercising by establishing a reward system (eg, 
encouraging patients to set weekly behavioral goals and to 
reward themselves in case of achievement, but not through 
food or inactivity).40 Encouraging patients to use cognitive 
rewards (eg, ‘I’ve been OK,’ ‘I’m doing great,’ and ‘I have the 
ability to lose weight and to have an active lifestyle’) once they 
reach their lifestyle goals it may also help patients reduce their 
frustration associated with limited weight loss and strengthen 
their confidence in controlling body weight and maintaining 
a healthy lifestyle. Positive reinforcements may also be used 
by clinicians, who should congratulate the patients on every 
success they achieve and should never criticize failures.91 
Criticism may produce guilt and loss of self-confidence, 
leading to attrition. An unconditional acceptance of patients’ 
behavior and a problem-solving approach to cope with barriers 
will preserve the clinician–patient relationship. This approach 
will also help patients understand that the long-term success 
in weight management is related to a set of skills rather than 
to willpower.
Stimulus control may also be facilitated by the involve-
ment of significant others.92 With the consent of patients, 
clinicians should involve significant others in the treatment 
program to create the ‘optimum’ environment for patients’ 
change. The needs vary from patient to patient, but generally 
include planning together a written shopping list, eating the 
same foods, exercising together, creating a relaxed environ-
ment, and reinforcing patients’ positive behaviors.
Alternative behaviors
This procedure is used to manage internal eating cues 
(eg, emotional stimuli). Patients are trained to identify these 
cues and to replace eating cues with alternative behaviors. 
Any alternative behavior works better if it is incompatible 
with eating (eg, writing, knitting, housekeeping, exercising, 
and taking a bath). Other behaviors (eg, listening to music or Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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reading) might not be appropriate, as people can easily eat 
and listen to music or read a book simultaneously.40
Cognitive procedures
Proactive problem solving
Proactive problem solving is used to address events that   hinder 
lifestyle weight control adherence. The typical problem-
  solving approach includes five steps.93 Step 1 encourages 
patients to detail the problem and the chain of events (ie, 
situations) that preceded the problem. Step 2 helps patients 
brainstorm any possible solution. Step 3 suggests patients list 
the pros and cons for each potential solution. In step 4, patients 
should choose the best option on the basis of the previous anal-
yses to be implemented for a fixed amount of time. Finally, 
during step 5, the patients evaluate the results achieved. If the 
solution fails, the process should be repeated.
Initially, it is recommended to practice problem solving 
in the session with the clinician, encouraging the patient to 
take the lead whenever possible. As homework, patients 
should be asked to practice their own problem-solving skills, 
looking out for events that would be liable to trigger changes 
in their eating or exercising and addressing them using the 
problem-solving procedure. Specifically, once patients iden-
tify a problem, they should write ‘Problem’ in the right-hand 
column of the monitoring record sheet and then turn the 
sheet over and write out the problem-solving steps. Patients 
should be advised against solving the problem mentally, as 
this is much less effective. The emphasis should be on help-
ing patients acquire the ability to address or forestall events 
that would otherwise trigger changes in eating or exercising. 
As it is important that problems are spotted early, patients 
should be encouraged to screen in advance for problems they 
will meet during the week. In this way, their problem solving 
becomes ‘proactive.’86
Cognitive restructuring
Cognitive restructuring is a technique used to help patients 
identify dysfunctional thoughts and cognitive distortions that 
interfere with their ability to maintain a lifestyle aimed at weight 
control and to replace them with more functional ones (see 
Figure 1).94,95 All-or-nothing thinking, in particular with regard 
to success or failure, is a common cognitive bias observed 
in patients during weight loss.40 In addition, for this activity, 
patients are recommended to practice cognitive restructuring 
during a session with therapists. Later, clinicians should give 
patients homework to practice cognitive restructuring every 
time they notice a tendency to decrease their efforts in lifestyle 
modification as a consequence of an event. Specifically, when 
patients identify a dysfunctional thought, they should write 
‘Dysfunctional thoughts’ in the right-hand column of their 
monitoring sheet and then turn the sheet over and address it by 
writing out the cognitive restructuring steps (see Figure 1).
New frontiers of lifestyle 
modification programs
At 3- to 5-year follow-up, 70%–80% of patients treated with 
lifestyle modification regained all the weight they had lost.96,97 
These data underline the fact that the major problem of lifestyle 
modification treatment is weight loss maintenance in the long 
term. Unfortunately, the mechanisms accounting for weight 
regain have not been completely understood yet, but they seem 
extremely complex, including biological, social, behavioral, 
(A) Event
Gained 1/2 kg this week
(B) Dysfunctional thoughts (B) Functional thoughts
(C) Consequence (C) Consequence
“It is a failure; I will never be able to
lose weight. I had better give up trying
to lose weight”
“It is not a failure, but just a set back.
It is difficult to lose weight, but not
impossible: I’ve done it before”
Reduced efforts Increased efforts
Figure 1 An example of cognitive restructuring. 
Notes: According to the cognitive model, the link between an activating event A) and the emotional or behavioral consequence C) is influenced by the belief B) about the 
activating event. when the belief contains cognitive bias (eg, as all-or-nothing thinking) as in the scenario on the left, the consequence tends to be unfavorable. However, if 
the beliefs about that event have been adequately challenged and substituted with more functional thoughts, the consequences are more favorable (scenario on the right).94Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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and cognitive factors. Nevertheless, the observation that at least 
20% of patients maintain all the amount of weight loss at 4-year 
follow-up98 indicates that weight loss maintenance is possible. 
In this section, we discuss three potential areas of intervention 
(biological, cognitive, and environmental) that might improve 
the long-term maintenance of weight loss.
Combining lifestyle modification  
with pharmacotherapy
One of the main factors implicated in the long-term failure 
of weight maintenance is the biological pressure to weight 
regain.99 It is, therefore, rational to evaluate the effect of com-
bining lifestyle modification with pharmacological therapies 
aimed to mitigate the biological pressure to weight regain. 
The available data suggest that this combined approach seems 
to improve both the amount of weight loss and the mainte-
nance of weight lost.100 The enhancement of weight loss is 
also associated with marked improvements in several meta-
bolic outcomes and risk factors of cardiovascular disease.101 
Two medications – orlistat and sibutramine – are currently 
approved in the United States for long-term weight loss.
A randomized controlled trial comparing the effects of life-
style modification and sibutramine (15 mg/day) either alone or in 
combination found that there were no differences in weight loss 
at 1-year weight for participants who received group-based life-
style modification alone versus those who received sibutramine 
alone.100 However, participants treated with group-based lifestyle 
modification and sibutramine achieved a 1-year weight loss 
nearly twice as large as that of either therapy alone.100 These 
data show that lifestyle modification and pharmacotherapy 
are equivalent when used separately, but additive when used 
in combination. Unfortunately, the preliminary analysis of the 
Sibutramine Cardiovascular Outcomes Trial,102 which assessed 
the safety of sibutramine in individuals with preexisting cardio-
vascular diseases or diabetes mellitus, showed a higher rate of 
cardiovascular disease events in the sibutramine group compared 
to placebo (11.4% versus 10.0%). On the basis of these results, 
sibutramine was withdrawn from the European market in Janu-
ary 2010,103,104 but it is still available in the United States.
The XENDOS (Xenical in the Prevention of Diabetes 
in Obese Subjects) randomly assigned 3305 participants to 
lifestyle plus placebo intervention or lifestyle changes plus 
orlistat who had a significant low cumulative incidence of type 
2 diabetes and a greater weight loss than those treated only 
with lifestyle modification.105 A few cases of serious adverse 
hepatic effects (eg, cholestatic hepatitis and subacute liver fail-
ure) have been reported with the use of orlistat, prompting the 
FDA to issue an update on the safety of orlistat in September 
2009.106 However, the drug can be still prescribed and can be 
also purchased over-the-counter at a lower dose (60 mg).
Some  combination  therapies  targeting  multiple 
hypothalamic pathways that regulate appetite and body weight 
are currently under investigation, but very few data have so far 
been reported on their long-term safety and efficacy.107,108
Addressing cognitive processes 
implicated in weight loss failure
The National Weight Control Registry (NWCR) has inten-
sively investigated individuals with long-term successful 
weight loss.109 The participants registered in the NWCR must 
have maintained a weight loss of $13.6 kg ($30 lb) for at 
least 1 year, and on an average, they must have maintained a 
32-kg (70 lb) weight loss for 6 years. The principal behaviors 
reported by ∼3000 NWCR participants were:109–111 i) self-
monitoring of food intake and body weight (at least once a 
week), ii) consuming a low-calorie (1300–1400 kcal/day) and 
low-fat diet (20%–25% of daily energy intake from fat), iii) 
eating breakfast every day, and iv) practicing regular physical 
activity to expend 2500–3000 kcal/week (eg, walking 4 miles/
day). However, the research has not clarified yet why some 
individuals stop practicing weight control behaviors after 
losing weight, while others maintain them.
As cognitive processes are involved in the maintenance of 
complex behaviors, such as eating and exercise, they are likely to 
play a key role in the process of weight regain or maintenance,112 
but have been scarcely evaluated by research.
The cognitive processes implicated in weight loss and 
weight maintenance have been tested in the QUOVADIS 
study, a large observational study on the quality of life 
of obese patients seeking treatment at 25 medical centers 
certified by the Italian Health Service for the treatment of 
obesity.113 The study provided three main results. First, treat-
ment attrition was associated with higher weight loss expec-
tations.88 Second, the amount of weight loss was predicted 
by increased dietary restraint and reduced dietary disinhi-
bition.114 Third, long-term weight maintenance (.3 years) 
was observed in patients satisfied with the results achieved, 
or confident to control their body weight without additional 
professional help,56 a construct similar to the concept of 
self-efficacy, which is associated with greater adherence 
to physical therapy.115 These data suggest that including 
specific strategies to address cognitive obstacles to weight 
loss and weight maintenance could improve the long-term 
effectiveness of lifestyle modification interventions.
Two books have been recently published with a major 
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in weight loss and maintenance,83,116 and some studies found 
that adding cognitive procedures to lifestyle modification is 
associated with better weight loss maintenance.117–121 However, 
a recent randomized control trial failed to observe a positive 
effect on long-term weight loss maintenance of a cognitive 
behavior intervention specifically designed to address the 
cognitive processes associated with weight regain.122
General strategies at population level  
to facilitate lifestyle modification
Lifestyle modification might have more chance to be more 
effective if supported by public health programs to change 
the ‘toxic’ environment promoting overeating and sedentary 
behaviors.123 Examples of a long list of possible interventions 
aimed at improving the dietary and lifestyle habits of the 
general population include i) modifying the urban design 
and favoring physical activity in the community (parks, 
sidewalks, and bike paths) and at school (physical fitness 
curricula), ii) regulating the aggressive economic policies 
promoting the purchase of processed foods, iii) increasing the 
opportunities for family interaction (eg, family gathering at 
meal time), iv) reducing the exposure of children to marketing 
of energy-dense, micronutrient-poor foods, v) preventing the 
collusion of schools in the sale of junk foods, vi) reducing 
the portion of the meals served in the restaurant, vii) teaching 
skills for preparing healthy food (implementing nutritional 
standards for food in school, preschool, and after-school 
programs; nutritional labeling of food; warning labels on 
‘junk food’), and viii) favoring the access of low-income 
ethnic and social groups to healthy food.124
Conclusions
Lifestyle modification plays a central role in the manage-
ment of MS. Programs based on lifestyle modification have 
improved in the last few years; recent data show that a modest 
long-term weight loss is associated with a marked reduction 
of the incidence of type 2 diabetes125 and the prevalence of 
MS.21 The promising results obtained with the inclusion of 
innovative procedures, such as combining lifestyle modifi-
cation with pharmacotherapy,100 using meal replacement,74 
setting higher physical activity goals,126 and long-term care,127 
raise optimistic expectations for an effective treatment of 
obesity and MS with lifestyle modifications.
More research is needed to understand the negative phenom-
enon of weight regain. The key role of cognitive processes in 
the success/failure in weight loss and weight maintenance56,88,114 
suggests that new cognitive procedures and strategies should 
be included in the traditional lifestyle modification programs, 
in order to help patients build a mind-set of long-term weight 
control. Lifestyle modification programs will be more   effective 
if supported by public health programs to change the environ-
ment where patients live. Only through the synergy of individu-
als and a society global response, the maximum benefit for 
patients with MS can be achieved, thus reducing the burden 
of advanced disease and premature death.48
Finally, the positive results obtained by lifestyle modifi-
cation programs in the management of MS should stimulate 
physicians to adopt a ‘team approach.’ General practitioners, 
as well as physicians working in metabolic units and treat-
ing patients with MS, should receive adequate training in 
cognitive behavioral therapy to engage patients in lifestyle 
modification. Engaged patients should then be referred to 
trained lifestyle counselors (eg, dieticians, psychologists, 
physical activity supervisors, and case managers) working 
closely with them, ideally in the same lifestyle modification 
unit, to implement the full lifestyle modification program.
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